首页>投融资
泽璟制药
增发
苏州泽璟生物制药股份有限公司总部位于昆山国家高新区，在上海张江高科技园区设有研发中心。公司主营业务是创新药物的自主研发、生产和销售。公司的使命是在中国研发高质量的生物新药以满足中国和其它国家患者的临床需求，改善其生活质量，延长其寿命。公司的目标是成为中国生物制药领域的领军企业，拥有领先的技术、优秀的技术团队、现代化的管理模式、充实的产品线和良好的盈利状况。
基本信息
-
公司全称苏州泽璟生物制药股份有限公司
-
类型创新药物研发、生产商
-
产业领域药品研发/制造、医药研发/制造、生物药、化学药
-
公司人数101~500人
-
地址江苏省昆山市玉山镇晨丰路209号
-
联系电话0512-57018310
-
邮箱admin01@zelgen.com
-
成立时间2009-03-17
投融资
-
2023-04-19定向增发12亿人民币财通基金管理正大制药投资普洛江山投资中信证券JP Morgan诺德基金管理瑞华投资广发基金
-
2023-04-19增发12亿人民币正大制药投资财通基金诺德基金管理普洛药业JP Morgan中信证券广发基金瑞华控股江山投资
-
2020-01-23上市20.26亿人民币未透露
-
2018-12-26战略融资未透露赛复资本德屹资本燕园首科资本东吴证券
-
2018-12-26战略投资未透露德屹资本燕创集团赛复资本东吴证券
-
2018-10-09C轮未透露璟晨投资
-
2018-10-09C轮未透露璟晨投资
-
2018-01-15B轮4亿人民币分享投资深创投中青国融民生保险北极光创投
-
2018-01-15B轮4亿人民币中青国融民生保险北极光创投深创投分享投资
-
2016-08-29A轮未透露国中创投
-
2016-08-29A轮未透露国中资本
-
2016-04-29天使轮未透露盈富泰克
-
2016-04-29天使轮未透露盈富泰克
- 加载更多
相关投融资企业
收并购
Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, founded in 2002 by Italian academics as a spin-off from the European Organization for Nuclear Research (CERN, Switzerland), develops diagnostic and therapeutic products, including PET radiopharmaceuticals. The company focuses on Personalized Medicine, aimed at providing treatments tailored to a patient's profile and disease, using predictive, preventive and personalized procedures. In January 2018, AAA became a subsidiary of Novartis AG.In July 2016, the company opened its first US manufacturing facility in Millburn, NJ. The Millburn plant served as a distribution center for NETSPOT.In April 2014, AAA opened a new office in the US located at Manhattan, NY. At that time, the company planned to set up a new manufacturing facility in the US.In February 2012, AAA planned to build a radiopharmaceutical facility in Murcia, Spain. The facility was expected to be completed within 18 months.By December 201
B轮
Veradermics Inc (美国)：Veradermics是一家位于美国的生物技术公司，专注于皮肤健康和美容产品的研发。公司的主要研究领域包括皮肤再生、抗衰老和皮肤修复。Veradermics利用其专有的生物材料和技术平台，开发了一系列高效的皮肤护理产品。公司的产品线包括抗衰老面霜、皮肤修复凝胶和皮肤再生面膜等。
B轮
Qnovia, formerly known as Respira Technologies, is focused on developing inhaled drug delivery platforms to deliver drugs for nicotine replacement therapy and cardiopulmonary diseases.In September 2022, the company changed its name from Respira Technologies to Qnovia.In September 2022, the company raised USD 17M in Series A funding led by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures,
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息